Core Viewpoint - Jianxin Superconductor officially listed on the Sci-Tech Innovation Board, becoming the 599th company on the board, amidst a surge in new stock listings and significant first-day gains for recent IPOs [2] Group 1: Market Performance - A total of 109 companies have gone public this year, with a first-day gain probability of 100% and an average first-day increase of 257.88% [2] - Among the newly listed Sci-Tech Innovation Board stocks, 17 have averaged a first-day increase of 250.86% [2] - Notable recent IPOs include Moer Thread-U, which saw a first-day increase of over 400%, and Muxi Co., which had a first-day increase of nearly 700% [2] Group 2: Company Overview - Jianxin Superconductor specializes in the R&D, production, and sales of core components for medical MRI equipment, including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of MRI equipment costs [3] - The company has developed a comprehensive product matrix in the superconducting field, including various types of superconducting magnets, and has become the leading independent supplier of superconducting magnets in the global MRI industry [4] Group 3: Technological Advancements - Jianxin has closed a 20-year technology gap with international giants in the field of zero-evaporation superconducting technology, achieving mass production of 1.5T zero-evaporation superconducting magnets and breaking the monopoly of European, American, and Japanese manufacturers [4] - The company has transitioned from a follower to a leader in the next-generation helium-free superconducting technology, successfully developing a fully helium-free superconducting magnet, recognized as the "first of its kind" by the Zhejiang Provincial Department of Economy and Information Technology [4] Group 4: Financial Performance - For the first nine months of 2025, the company reported revenue of 393 million yuan, a year-on-year increase of 37.34%, and a net profit of 47.62 million yuan, up 38.54% year-on-year [7] - The company projects revenue for 2025 to be between 580 million and 620 million yuan, representing a year-on-year growth of 36.31% to 45.71%, with an expected net profit of 72 million to 77 million yuan, reflecting a growth of 29.07% to 38.03% [8] Group 5: Research and Development - The company has consistently increased its R&D investment, with expenditures of 20.33 million yuan, 24.42 million yuan, and 27.65 million yuan from 2022 to 2024, resulting in a compound annual growth rate of 16.61% [8] - R&D investment accounted for 5.86% of total revenue over three years, with a rise to 6.65% in the first half of 2025, indicating a commitment to enhancing product and technology development [8]
月内科创板新股首日平均涨超350%，健信超导今日上市，全球最大的超导磁体独立供应商，从追光到引领，助力MRI核心部件国产化突破